IgA Nephropathy: From Pathogenesis to Precision Medicine

Learning Objectives

By the end of this module, you will be able to:

Explain the four-hit pathogenesis model and identify therapeutic targets at each stage
Recognize clinical presentations and risk stratify for treatment intensity
Compare current and emerging therapeutic options with efficacy data
Apply risk-based treatment decisions to patient scenarios
Understand pregnancy considerations in reproductive-age patients

What Makes IgA Nephropathy Unique?

Global Epidemiology: - Most common primary kidney disease worldwide - Prevalence varies: ~45% of primary GN in Asia, ~20% in Europe, ~10% in North America - Predominates in young adults (peak 20-40 years) - Male:female ratio approximately 2:1

Natural History: - 30-40% progress to kidney failure over 20 years without intervention - Highly variable course: some remain stable, others progress rapidly - Characterized by episodic gross hematuria often following respiratory infections

Pathophysiology: IgA-containing immune complexes deposit in glomerular mesangium, triggering inflammatory cascades leading to progressive scarring.

The Four-Hit Pathogenesis Model: Therapeutic Framework

Understanding disease mechanisms enables rational therapeutic selection targeting specific pathogenic steps.

Hit 1: Abnormal Antibody Production (Gut-Associated)

Location: Gut-associated lymphoid tissue, particularly Peyer’s patches in small intestine

What Goes Wrong: - Environmental triggers, genetic factors, or infections stimulate production of galactose-deficient IgA1 (Gd-IgA1) - These abnormal IgA antibodies lack important sugar modifications - Altered glycosylation promotes aggregation and immune complex formation

Therapeutic Target: - TARPEYO (targeted-release budesonide): Delivers steroid specifically to Peyer’s patches - APRIL inhibitors: Block A Proliferation-Inducing Ligand controlling IgA class switching in gut

Hit 2: Autoimmune Response (Anti-Glycan Antibodies)

What Develops: - Immune system recognizes abnormal IgA as “foreign” - Produces anti-glycan autoantibodies targeting galactose-deficient regions - Creates autoimmune attack against body’s own antibodies

Cascade Effect: - IgA1-specific glycan modifications become immunogenic - Antibodies bind to the abnormal IgA, forming pathogenic complexes

No Direct Therapeutic Target Yet: - Future approaches may involve tolerizing autoimmune responses - Current therapy focuses on downstream steps

Hit 3: Immune Complex Formation

Result: Formation of circulating immune complexes with: - Altered size properties (too small for normal clearance) - Altered charge properties - Enhanced propensity for glomerular deposition

Therapeutic Target: - Complementary strategies reducing circulating complex load - SGLT2 inhibitors may help prevent progression

Hit 4: Kidney Deposition and Inflammation

Pathology: - Complexes deposit in glomerular mesangium - Complement activation triggered - Inflammatory cell infiltration - Fibroblast proliferation → progressive scarring

Therapeutic Targets: - Sparsentan: Dual endothelin A + angiotensin receptor blockade - Iptacopan: Factor B inhibitor blocking alternative complement pathway - Conventional therapy: ACE-I/ARB, corticosteroids

Clinical Presentation Patterns

Classic Presentation (40% of Cases)

Presentation: Gross hematuria within 1-3 days of upper respiratory infection

Key Features: - “Tea-colored” or “cola-colored” urine - Peak in young adults - Often misattributed to urinary tract infection initially - Represents acute glomerular inflammation triggered by respiratory pathogen

Typical Labs: Normal kidney function, proteinuria 1-3 g/day initially

Asymptomatic Urinary Abnormalities (30% of Cases)

Presentation: Microhematuria and proteinuria found on routine screening

Key Features: - No gross hematuria - May have slowly progressive disease without obvious symptoms - Often in older patients or with incidental screening

Clinical Significance: May represent slowly progressive IgA nephropathy requiring monitoring even without symptoms

Nephrotic/Nephritic Syndrome (20% of Cases)

Presentation: Significant proteinuria >3.5 g/day with hypoalbuminemia and edema

Key Features: - More aggressive disease phenotype - Combined nephrotic and nephritic features - Requires intensive intervention

Prognosis: Worse short-term outlook; requires maximum therapeutic intervention

Acute Kidney Injury (10% of Cases)

Presentation: Rapid decline in kidney function

Pathology: Often associated with crescentic glomerulonephritis

Clinical Significance: Most severe form; requires emergent aggressive treatment

Risk Stratification for Treatment Planning

Low-Risk Patients

Definition: - Proteinuria <1 g/day - Normal kidney function (eGFR >90) - Minimal histologic changes on biopsy

Management: - ACE inhibitor or ARB optimization (primary therapy) - Blood pressure target <130/80 mmHg - Lifestyle modification (salt restriction, protein moderation) - Close monitoring with 3-6 month urinalysis

Monitoring: Annual assessment adequate

Moderate-Risk Patients

Definition: - Proteinuria 1-3 g/day - Stable kidney function - Moderate histologic changes

Management: - TARPEYO indicated for risk reduction - Combined with optimized ACE-I/ARB - Close monitoring for progression

Monitoring: 3-6 month intervals

High-Risk Patients

Definition: - Proteinuria >3 g/day - Declining kidney function - Severe histologic changes including crescents

Management: - Sparsentan or combination therapy - More intensive monitoring - May require specialist referral

Monitoring: Monthly initially with clinic/lab assessment

Very High-Risk Patients

Definition: - Proteinuria >5 g/day plus declining eGFR - Crescentic disease with rapidly declining function - Multiple organ systems involved

Management: - Combination therapy (endothelin antagonist + complement inhibitor + supportive care) - Specialist (nephrologist) co-management - Weekly monitoring initially

Current Therapeutic Armamentarium

Foundation Therapy: RAAS Blockade

First-line for ALL patients: - ACE inhibitor or angiotensin receptor blocker - Dual therapy (ACEi + ARB) not recommended - Maximize dose to highest tolerated level - Target: ≥30% proteinuria reduction

Mechanism: - Reduces glomerular hyperfiltration - Provides anti-inflammatory and anti-fibrotic effects - Lowers blood pressure

TARPEYO (Targeted-Release Budesonide)

Mechanism: Delivers budesonide specifically to Peyer’s patches in intestine, targeting presumed site of abnormal IgA production while minimizing systemic steroid exposure

Clinical Evidence - NefIgArd Trial: - 27% proteinuria reduction at 9 months - 50% reduction in eGFR decline rate over 2 years - Sustained benefits at 15-month follow-up

Optimal Patient Selection: - Moderate-risk patients with proteinuria 1-3 g/day - Desire to avoid systemic immunosuppression - Need for intervention beyond supportive care

Practical Use: - Oral capsule administration for 9 months - Common side effects: peripheral edema (17%), hypertension (12%) - Advantage: Avoids serious complications of systemic steroids

Sparsentan (FILSPARI)

Mechanism: First-in-class dual endothelin A receptor and angiotensin II type 1 receptor antagonist in single molecule

Clinical Evidence - PROTECT Trial: - 49.8% proteinuria reduction with sparsentan vs. 15.1% with maximum-dose irbesartan - Slower eGFR decline: 1.2 mL/min/1.73m²/year treatment effect - Two-year data shows sustained benefit

Optimal Patient Selection: - High-risk patients with proteinuria >1 g/day - Need for maximum efficacy intervention - Patients requiring combined anti-proteinuric and nephroprotective effects

Key Advantage: No fluid retention or heart failure observed (distinguishes from other endothelin blockers)

Monitoring: Liver function tests required through REMS program

Iptacopan (FABHALTA)

Mechanism: Selective factor B inhibitor blocking alternative complement pathway amplification while preserving classical and lectin pathway function

Clinical Evidence - APPLAUSE-IgAN: - 38.3% proteinuria reduction at 9 months - Composite kidney outcome improvement (NNT = 14)

Optimal Patient Selection: - Patients with evidence of active complement activation - Non-immunosuppressive therapy preference - Requires meningococcal vaccination

Practical Considerations: - Prescribing limited to certified providers through REMS - Infection monitoring required - Continued approval depends on eGFR benefit demonstration

Emerging Therapies: The Future Pipeline

APRIL Inhibitors (Next-Generation Therapy)

Target: A Proliferation-Inducing Ligand (APRIL) controls IgA class switching in gut lymphoid tissue

Clinical Data - Sibeprenlimab (VISIONARY Trial): - 51.2% proteinuria reduction (highest efficacy to date) - Excellent safety profile - Subcutaneous injection every 4 weeks - Disease-modifying potential (addresses pathogenic source)

Significance: Represents highest efficacy demonstrated and most direct hit on pathogenic mechanism

Combination Strategies

Rationale: Multiple pathogenic pathways present opportunity for synergistic targeting

Investigational Approaches: - APRIL inhibitor + complement inhibitor (upstream + downstream) - Endothelin antagonist + SGLT2 inhibitor (anti-proteinuric + anti-fibrotic) - Triple therapy for very high-risk patients

Future Direction: Biomarker-guided combination selection based on individual pathway activation

Treatment Decision Framework

Risk Level	Proteinuria	Recommended Approach	Monitoring
Low	<1 g/day	ACE-I/ARB optimization	Annual
Moderate	1-3 g/day	TARPEYO + ACE-I/ARB	3-6 months
High	>3 g/day	Sparsentan or combination	Monthly initially
Very High	>5 g/day + declining eGFR	Combination therapy + specialist	Weekly initially

Special Populations: Case-Based Learning

Case 1: Reproductive-Age Female

Scenario: 26-year-old planning pregnancy with stable IgA nephropathy

Challenge: Most novel therapies (sparsentan, complement inhibitors, APRIL inhibitors) contraindicated in pregnancy due to teratogenic potential

Management Approach: 1. Optimize supportive care with pregnancy-compatible agents 2. Continue ACE-I until pregnancy confirmed, then discontinue 3. Plan for multidisciplinary obstetric-nephrology collaboration 4. Close monitoring during pregnancy and postpartum period

Learning Point: Reproductive health planning essential for young adults with IgA nephropathy

Case 2: Aggressive Disease with Crescents

Scenario: 32-year-old male with 4.2 g/day proteinuria, eGFR decline 90→65 over 6 months, crescentic lesions on biopsy

Assessment: High-risk disease requiring maximum intervention

Treatment Strategy: - Initiate sparsentan for dual mechanism benefit - Plan combination therapy if inadequate response at 3-6 months - Close monitoring with monthly clinic and lab assessment - Consider rheumatology/nephrology co-management

Learning Point: Rapidly progressive disease requires immediate intensive intervention

Monitoring and Assessment Strategies

Proteinuria Monitoring

Check spot UPCR every 3-6 months during treatment
Look for ≥30% reduction as meaningful response
Response may take 3-6 months to become apparent
Monitor for proteinuria rebound with therapy discontinuation

Kidney Function Assessment

Monitor eGFR trends rather than absolute values
Stable or slowing decline rate indicates therapeutic benefit
Assess for premature GFR decline suggesting treatment failure

Safety Monitoring

TARPEYO: Hypertension, glucose monitoring
Sparsentan: Liver function tests, blood pressure
Iptacopan: Infection surveillance, meningococcal vaccination verification
All agents: Serum creatinine for acute kidney injury

Practice Questions

Question 1: A 28-year-old woman with IgA nephropathy and 2.8 g/day proteinuria plans pregnancy in 6 months. Which therapeutic approach is most appropriate?

Start sparsentan for maximum efficacy now
Initiate TARPEYO before pregnancy
Maximize ACE-I therapy; discuss transitioning to pregnancy-compatible management
Defer all therapy until postpartum period

Correct Answer: C — ACE inhibitors provide maximum nephroprotection but must be discontinued once pregnancy is confirmed due to teratogenicity. Early optimization before pregnancy then transition to alternative agents represents appropriate approach. Most novel therapies contraindicated in pregnancy.

Question 2: Which mechanism best explains sparsentan’s superior proteinuria reduction compared to standard ACE inhibitors alone?

More potent angiotensin receptor blockade
Dual pathway targeting with synergistic effects
Selective complement inhibition
Direct anti-inflammatory properties

Correct Answer: B — Sparsentan combines endothelin A receptor antagonism with angiotensin receptor antagonism in a single molecule, providing synergistic renoprotection through dual pathway inhibition.

Question 3: A 35-year-old with IgA nephropathy starts iptacopan (FABHALTA) but develops recurrent sinusitis and otitis within 2 months. What is the most likely explanation?

Drug intolerance requiring immediate discontinuation
Complement inhibition increases infection risk; enhance monitoring and verify meningococcal vaccination
Unrelated coincidence; continue therapy
Indication for combination with prophylactic antibiotics

Correct Answer: B — Selective complement pathway inhibition increases infection risk by 2-3 fold. Meningococcal vaccination mandatory before therapy. Enhanced infection surveillance required. This is an expected risk, not indication for discontinuation, but requires active management.

Clinical Pearls

Risk stratification drives therapy — not all IgA patients need same treatment intensity
ACE-I/ARB optimization is foundation — all patients require maximal RAAS blockade
TARPEYO targets disease source — delivers therapy to Peyer’s patches
Sparsentan dual mechanism — superior efficacy for high-risk patients
Fertility planning essential — most novel therapies contraindicated in pregnancy
Proteinuria decline takes time — expect 3-6 months for therapeutic effect
Monitoring strategy depends on therapy — different agents require different surveillance

Summary

IgA nephropathy represents a paradigm shift in nephrology from empiric immunosuppression to mechanism-based precision medicine. Understanding the four-hit pathogenesis model enables rational therapeutic selection targeting specific disease mechanisms. Risk stratification guides appropriate therapy intensity from supportive care to combination approaches. Novel agents including TARPEYO, sparsentan, and iptacopan expand therapeutic options with improved efficacy and safety profiles. The robust development pipeline promises continued advancement with APRIL inhibitors demonstrating highest efficacy to date. Future directions include biomarker-guided combination therapy tailored to individual pathway activation patterns. For medical students and residents, IgA nephropathy provides an excellent model of translating mechanistic understanding into effective therapies and demonstrates the power of precision medicine approaches in modern nephrology.